Clinical trial · Interventional
Acitretin Plasma Levels Under Hemodialysis
NCT00488384CI-TRIAL-00033850withdrawnPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of subjects
Summary
Brief summary (as posted)
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Squamous Cell | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemopreventive application (Acitretin) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- a
- description
- single arm only. Only open label treatment anticipated
- interventionNames
- Drug: Chemopreventive application (Acitretin)
Primary outcomes (1)
- measure
- Plasma levels acitretin
- timeFrame
- 2009
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Hemodialyis patients with at least one case of in-situ or invasive squamous cell carcinoma of the skin Exclusion criteria: * Hepatopathy * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.